Literature DB >> 6838358

Total thyroidectomy for Hürthle cell neoplasm of the thyroid.

S R Gundry, R E Burney, N W Thompson, R Lloyd.   

Abstract

The treatment of Hürthle cell neoplasms of the thyroid is controversial because of a lack of information about their clinical behavior and long-term follow-up. We reevaluated our experience of the past 33 years and compared our early experience with the more aggressive surgical approach used during the past ten years. We treated 62 patients with Hürthle cell neoplasm from 1949 through 1982. Twenty-six patients had benign neoplasms and 35 had malignant neoplasms proven by capsular or vascular invasion or nodal metastasis. Fourteen deaths were directly attributable to recurrent or metastatic disease, three among those with benign lesions. An aggressive surgical approach, involving total thyroidectomy or early-completion total thyroidectomy following lobectomy for all tumors histologically malignant or larger than 2 cm, resulted in a lower recurrence rate (21% v 59%) and fewer operations per patient (1.7 v 2.9) than in patients having other operations.

Entities:  

Mesh:

Year:  1983        PMID: 6838358     DOI: 10.1001/archsurg.1983.01390050013002

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  24 in total

Review 1.  Endemic goiter and endemic thyroid disorders.

Authors:  E Gaitan; N C Nelson; G V Poole
Journal:  World J Surg       Date:  1991 Mar-Apr       Impact factor: 3.352

Review 2.  Benign Hürthle cell tumors of the thyroid: a diagnosis to be trusted?

Authors:  C S Grant; D Barr; J R Goellner; I D Hay
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

Review 3.  Evolution of the histologic classification of thyroid neoplasms and its impact on clinical management.

Authors:  B Xu; R Ghossein
Journal:  Eur J Surg Oncol       Date:  2017-05-18       Impact factor: 4.424

4.  Hürthle cell neoplasms of the thyroid: are there factors predictive of malignancy?

Authors:  H Chen; T L Nicol; M A Zeiger; W C Dooley; P W Ladenson; D S Cooper; M Ringel; S Parkerson; M Allo; R Udelsman
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

5.  Flow cytometric DNA measurements in benign and malignant Hürthle cell tumors of the thyroid.

Authors:  J J Ryan; I D Hay; C S Grant; L M Rainwater; G M Farrow; J R Goellner
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

6.  Surgical treatment of Hurthle cell tumors of the thyroid.

Authors:  Tzu-Chieh Chao; Jen-Der Lin; Miin-Fu Chen
Journal:  World J Surg       Date:  2005-02       Impact factor: 3.352

7.  Poorly differentiated oncocytic (hürthle cell) follicular carcinoma: an institutional experience.

Authors:  Shuting Bai; Zubair W Baloch; Teresa D Samulski; Kathleen T Montone; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2015-05       Impact factor: 3.943

8.  Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas.

Authors:  M C Nascimento; H Bisi; V A Alves; A Longatto-Filho; C T Kanamura; G Medeiros-Neto
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 9.  The significance of hurthle cells in thyroid disease.

Authors:  Jennifer Cannon
Journal:  Oncologist       Date:  2011-09-30

10.  Factors predicting malignancy of Hürthle cell tumors of the thyroid: influence on surgical treatment.

Authors:  Adolfo Pisanu; Luigi Sias; Alessandro Uccheddu
Journal:  World J Surg       Date:  2004-08-03       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.